白云山:乙肝解毒胶囊等获补充申请批准

格隆汇资讯
28 Mar

格隆汇3月28日丨白云山(00874.HK)发布公告,近日,公司分公司广州白云山医药集团股份有限公司白云山制药总厂(以下简称“白云山制药总厂”)收到国家药监局签发的《药品补充申请批准通知书》。白云山制药总厂本次获得乙肝解毒胶囊和紫花杜鹃胶囊《药品补充申请批准通知书》,完善了上述药品的安全性等信息,有助于该药品的安全、有效、合理使用,有利于提升该产品的市场竞争力。本次获得《药品补充申请批准通知书》,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10